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Abstract
Background: The self-expandable COMPLETE™ stent (Medtronic) has greater elasticity, allowing it to regain its shape
after the compression force reduces, and has higher trackability, thus is easier to maneuver through tortuous vessels,
whereas the balloon-expandable SCUBA™ stent (Medtronic) has higher radial stiffness and can afford more accurate
placement without geographic miss, which is important in aortoiliac bifurcation lesions. To date, there have been no
randomized control trials comparing efficacy and safety between the self-expanding stent and balloon-expandable
stent in advanced atherosclerotic iliac artery disease.
Methods/design: The purpose of our study is to examine primary patency (efficacy) and incidence of stent fracture
and geographic miss (safety) between two different major representative stents, the self-expanding nitinol stent
(COMPLETE-SE™) and the balloon-expanding cobalt-chromium stent (SCUBA™), in stenotic or occlusive iliac arterial
lesions. This trial is designed as a prospective, randomized, multicenter trial to demonstrate a noninferiority of SCUBA™
stent to COMPLETE-SE™ stent following balloon angioplasty in iliac arterial lesions, and a total of 280 patients will be
enrolled. The primary end point of this study is the rate of primary patency in the treated segment at 12 months after
intervention as determined by catheter angiography, computed tomography angiography, or duplex ultrasound.
Discussion: The SENS-ILIAC trial will give powerful insight into whether the stent choice according to deployment
mechanics would impact stent patency, geographic miss, or stent fracture in patients undergoing stent implantation
in iliac artery lesions.
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Background
For aortoiliac occlusive disease, iliac artery angioplasty with
stenting has been a good alternative treatment modality,
and endovascular revascularization can be considered
without initial extensive conservative treatment [1–5]. The
technical and initial clinical success of percutaneous trans-
luminal angioplasty (PTA) of iliac artery stenosis exceeds
90 % in the literature; in addition, the technical success rate
of recanalization of obstructive long lesions of iliac artery is
80–85 % with or without additional fibrinolysis [6].
As new types of stents and technical developments
have been introduced, more extensive and multifocal
iliac lesions have been treated with endovascular
procedures [7–11]. Low morbidity and mortality as
well as up to 90 % technical success rate guarantee
the endovascular-first approach and the patency rates with
stenting of iliac arteries compare favorably with those of
surgical revascularization. In experienced centers, Trans-
Atlantic Inter-Society Consensus (TASC) type D lesions
might be also primarily treated percutaneously [12–14].
In endovascular repair for iliac lesions, unlike the
infrapopliteal revascularization strategy, routine stent
placement with a PTA strategy has been generally
accepted [15]. It was seen in a study of 250 patients
undergoing either PTA alone or PTA with provisional
stenting that the provisional stenting arm was associated
with more than a 2.5-fold reduction (10 vs 4 %) in
immediate failures, although long-term results in the
two groups were similar [16]. In a meta-analysis of iliac
artery intervention studies, the risk of long-term failure
was reduced by 39 % after stent placement compared
with PTA and the technical success rate was higher after
stent placement [7]. A study comparing angioplasty
alone with angioplasty plus stenting for complex iliac
artery disease showed that cumulative primary patency
rates were 78 % at 1 year, with a secondary patency rate
more than 80 % at 32 months, with reduction in long-
term failure of 39 % when stents were used [17]. In this
analysis, stenting improved the 4-year primary patency
rates by approximately 10 % for both patients treated for
claudication or critical ischemia, and patients treated for
iliac stenosis and occlusions.
Stents for iliac artery disease are classified as self-
expandable and balloon-expandable according to the
mechanics of stent deployment, and as nitinol, stainless
steel and others according to stent material. Currently,
the choice of balloon- versus self-expandable stent is de-
termined mainly by operator preference. Self-expanding
stents are usually made of nitinol, an alloy of nickel and
titanium, and stainless steel. Nitinol alloys are most
commonly known for their super-elasticity and thermal
shape memory [18]. Generally, self-expanding stents
have greater elasticity, allowing them to regain their
shape after the compression force reduces. Another
advantage of self-expanding stents is their higher
trackability, meaning they are easier to maneuver
through tortuous vessels or pass the aortic bifurcation
from the contralateral approach. Balloon-expandable
stents are usually made of stainless steel. Balloon-
expandable stents are characterized by much greater
radial strength compared to self-expanding stents.
The main advantages of balloon-expandable stents are
the higher radial stiffness and more accurate placement -
avoiding geographic miss, which is especially important in
aortoiliac bifurcation lesions. Balloon-expandable stents
generally have higher radio-opacity, which facilitates
accurate placement [19]. In addition, balloon-expandable
stents are generally considered more appropriate in rigid
and straight lesions [20, 21].
There are some indirect comparative studies that
compared balloon-expandable with self-expandable
stents [22, 23], and one direct study that compared
self-expandable with balloon-expandable stents in a
human ex vivo [24]. The outcome of two different
self-expanding stents (nitinol versus stainless steel) for
the treatment of iliac artery lesions was indirectly
compared in a multicenter prospective randomized
trial. In the CRISP-US trial [22], the 9-month composite
end-point rate was equivalent for the SMART stent versus
the Wallstent (6.9 vs. 5.9 %), with low rates of restenosis
(3.5 vs. 2.7 %), death (2.0 vs. 0.0 %), and revascularization
(2.0 vs. 4.0 %) in both groups. Primary patency at
12 months was 94.7 and 91.1 % with the SMART stent
and Wallstent, respectively. The MELODIE study
demonstrated that The Express LD balloon-
expandable stents were indirectly similar to the Pal-
matz balloon- expandable stent for primary patency
(92.1 % at 6 months and 87.8 % at 2 years) [23]. Gre-
nacher et al. reported that self-expanding stents pre-
sented considerably lower radial expansion force and
lower degree of precision than balloon-expandable
stents in a human cadaver bifurcation model [24].
However, there is no randomized comparative study
that compares primary patency rates of the two differ-
ent types of stent (self-expandable versus balloon-
expandable) in patients with iliac artery disease.
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Therefore, in this study, we will compare primary
patency rates of self-expandable stents and balloon-
expandable stents in real-world clinical practice. In
addition, we would like to ascertain whether there are
differences in safety, including the incidence of
geographic miss rate and stent fracture rate, between
both stent groups in steno-occlusive lesions, especially
for aortoiliac bifurcation lesions.
Method/design
Study objectives, hypothesis, and design
The primary purpose of our study is to compare primary
patency between self-expandable nitinol stents and
balloon-expandable cobalt-chromium stents in real-world
clinical practice (COMPLETE-SE™ versus SCUBA™,
Medtronic, Minneapolis, MN, USA) in stenotic or occlu-
sive iliac arterial lesions. The secondary purpose is to as-
certain whether there is a difference in safety, including
the incidence of geographic miss rate and stent fracture
rate between both groups in patients undergoing stent
implantation in iliac lesions. This is a prospective,
randomized, multicenter trial to assess the efficacy and
safety of the COMPLETE-SE™ versus the SCUBA™ stent
by provisional stenting after balloon angioplasty for steno-
occlusive iliac arterial lesions. A description of this manu-
script according to the SPIRIT guidelines is presented in
Additional file 1
The protocol of the trial has been registered with the
National Institutes of Health Clinical Trials Registry
(registration number: NCT01834495) and a brief flow
chart of the whole study is summarized in Fig. 1.
Study population
Patients at least 20 years of age who have moderate or
severe intermittent claudication or critical limb ischemia
(CLI), Rutherford score of 2 to 6, except for any patient
who has undergone or plans to have a major amputa-
tion) will be screened for study enrollment. Prior to inclu-
sion, morphological examinations such as computed
tomography (CT) and magnetic resonance imaging (MRI)
are not necessarily needed. However, we will usually
examine the CT angiography prior to the intervention. A
patient will be enrolled if they meet all of the inclusion cri-
teria and have none of the exclusion criteria. Inclusion cri-
teria consist of clinical and anatomical criteria.
The clinical inclusion criteria are as indicated below:
(1) Symptomatic peripheral artery disease with moderate
to severe claudication (Rutherford score of 2 to 3)
(2) Chronic CLI with resting ischemic pain (Rutherford
score of 4)
(3) Chronic CLI with ischemic ulcers (Rutherford score
of 5 to 6)
(4) Patients must provide written informed consent
The anatomical inclusion criteria are as indicated below:
(1) Stenosis of more than 50 %
(2) Occlusion of the ipsilateral iliac artery
(3) Patent (≤50 % stenosis) ipsilateral femoropopliteal
artery, or concomitantly treatable ipsilateral
femoropopliteal lesions (≤30 % residual stenosis),
and at least one patent (less than 50 % stenosis)
tibioperoneal run-off vessel. We will not exclude
patients who have undergone femoral endareterect-
omy. If inflow and outflow disease can be treated
(except by bypass surgery), we will enroll these
patients
Exclusion criteria include the following:
Fig. 1 Flow chart of the enrolled patients
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– Failure to provide written informed consent
– A history of major bleeding within the prior
2 months
– Known hypersensitivity or contraindication to
any of the following medications: heparin, aspirin,
clopidogrel, cilostazol, or contrast agent
– Acute limb ischemia
– Previous bypass surgery or stenting of the ipsilateral
iliac artery
– Untreated inflow disease of the distal aorta
(>50 % stenosis or occlusion)
– Patients who have undergone major amputation
(amputation of above the ankle) or major
amputation is planned or required
– Patients with a life expectancy of less than 1 year
due to comorbidities
Randomization and interventions
Prior to the endovascular intervention, informed consent
(see Additional file 2) will be obtained from all partici-
pants by investigators. Aspirin and clopidogrel will be
administered at least 12 hours before the procedure.
Prior to the intervention, 70 to 100 units/kg of unfrac-
tionated heparin will be administered. Endovascular in-
terventions will be carried out percutaneously, by
placing a 6–8Fr sheath at the femoral artery via an ante-
grade approach or a contralateral crossover technique.
In selected cases, a retrograde approach (from the distal
superficial femoral artery (SFA), popliteal artery, or pedal
arteries) and/or brachial approach will be allowed. Diag-
nostic angiography will be performed in two different
views at least 30 to 45° apart to evaluate the structure of
the target lesion. Femoropopliteal and tibial arteries will
be visually checked for the presence of distal lesions. To
document the precise location of the lesion and the site
of the intervention, we will recommend the use of a
ruler. In cases of total occlusion, both intraluminal and
subintimal methods of recanalization will be allowed.
During the procedure, the use of other special devices
will be allowed; for example reentry devices OUTBACK™
catheters (Cordis Corp., Miami Lakes, FL, USA) and
Offroad catheters (Boston Scientific, Natick, MA, USA),
chronic total occlusion (CTO) devices Frontrunner
(Cordis Corp., Miami Lakes, FL, USA) and Truepath
(Boston Scientific, Natick, MA, USA), and atherectomy
devices such as SilverHawk™ and TurboHawk™ (Covi-
dien, Plymouth, MN, USA). After the successful passage
of the guidewire, predilation of the target lesion with an
optimally sized balloon will be performed prior to stent
implantation. Recommended minimal balloon dilation
time is 120 seconds. Then, if there is a residual pressure
gradient of ≥10 mmHg, residual stenosis of ≥30 %, or
flow-limiting dissection, the balloon angioplasty results
will be considered as suboptimal results. Subsequently,
web-based randomization for stent selection will be per-
formed. Patients will be randomly allocated to one of
two groups, the balloon-expandable or self-expandable
stent group, according to the stent deployment method.
Random allocation of the patients will be performed via
a web-based computerized program separately managed
at the Cardiovascular Intervention Research Institute
(CIRI), Korea University Guro Hospital, Seoul, Republic
of Korea. Patients will be randomized in a 1:1 manner
according to two different stents (SCUBA™ versus
COMPLETE-SE™). The stents will be implanted to ex-
tend 10 mm proximally and distally from the margins of
the target lesion with luminal narrowing of ≥50 %. A
proper stent size will be selected after review of the
baseline angiography results. If the stent is randomized
to the COMPLETE-SE™, a stent with a diameter 1 to
2 mm larger than that of the true vessel lumen will be
selected. However, if the stent is randomized to the
SCUBA™ stent, a stent of equal size to the reference ves-
sel diameter will be selected to prevent iliac artery in-
jury. Spot stenting or full lesion coverage will be decided
at the physician’s discretion. When multiple stents are
required, the margins of the stents should be overlapped
by at least 10 mm. Adjuvant postdilation after the stent-
ing will be performed strictly within the stented seg-
ment, with up to 10 % oversizing of the postdilation
balloon.
The self-expandable COMPLETE-SE™ stent has three
distinct crown configurations, and an alternating
connection pattern minimizes crown-to-crown inter-
action and provides optimal flexibility, foreshortening,
and lesion coverage for each stent size. The triaxial
deployment design includes an inner shaft, a retractable
sheath, and a stabilizing sheath, which reduces friction
and allows the retractable sheath to move back freely.
This decreases the amount of force required to deploy
the stent, making deployment easy and accurate.
Diameter and length of self-expandable COMPLETE-
SE™ stents are 5–10 mm and 20, 40, 60, 80, 100, 120,
and 150 mm, respectively. Balloon-expandable SCUBA
stents are composed of thin cobalt-chromium struts, un-
like other stainless steel stents, and have a closed-cell
design for tight scaffolding and appropriate radial
strength in iliac lesions. Diameter and length of balloon-
expandable SCUBA™ stents are 6–10 mm and 20, 30, 40,
and 60 mm, respectively. The entire stent size (the
COMPLETE-SE™ and SCUBA™ stent) is now 6-Fr sheath
compatible. We will use either a 0.035” or 0.018” wire
system and implant either a SCUBA™ or COMPLETE-
SE™ stent. All ipsilateral femoropopliteal arterial lesions
should be treated with angioplasty and/or stenting
concomitantly and residual stenosis should be less than
50 %. Treatment of tibioperoneal lesions is recom-
mended only in cases of CLI. There should exist at least
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one patent (<50 % stenosis) tibioperoneal run-off vessel
with good antegrade flow. A final angiography will be
performed after the intervention in both groups, with
the use of the same angles and magnifications used at
the baseline angiograms. Simultaneously, reference ves-
sel diameter (RVD), minimal luminal diameter (MLD),
percent diameter stenosis, and acute gain should be
measured. The RVD will be obtained from averaging
5-mm segments proximal and distal to the lesion.
Technical success will be defined as successful access,
deployment of the stent, and less than 30 % diameter
residual stenosis after the revascularization. For postpro-
cedural medication, aspirin 100 mg and clopidogrel 75 mg
will be administered once daily for at least 12 months.
Cilostazol would be permitted as the third antiplatelet at
the physician’s discretion. After enrollment and index
procedure, clinical follow-up will be planned at 1, 6, and
12 months to evaluate clinical outcomes and ankle-
brachial index (ABI) score. In addition, a follow-up cath-
eter angiography, CT angiography, or duplex ultrasound
will be recommended to all patients at 12 months, accord-
ing to local clinical practice. The investigators will be
urged to follow up on patients, either by office visits or by
telephone contacts, as necessary. Patient adherence to the
study drug and side effects will be checked and monitored
at every outpatient visit. The decision of drug discontinu-
ation will be discussed and checked at the physician’s
recommendation.
Participants have the right to withdraw from the study
at any time for any reason. The principal investigator
also has the right to withdraw patients from the study in
the event of protocol violations, administrative reasons,
or other reasons, e.g., the participant is no longer being
treated at a hospital included in the study. It is under-
stood by all concerned that an excessive rate of with-
drawals can render the study uninterpretable; therefore,
unnecessary withdrawal of patients should be avoided.
Outcome measures
The primary end point of this study is the patency rate
(stenosis of at least 50 % of the luminal diameter) on
catheter or CT angiography or <2.5 of peak systolic
velocity ratio (PSVR; peak systolic velocity within the
area of stenosis divided by peak systolic velocity in a
normal adjacent proximal artery segment) in the treated
segment at 12 months after the intervention.
The secondary end points are as follows: (1) geo-
graphic miss rate (mild, moderate, severe); geographic
miss refers to stent deployment to any area of the vessel
that was intended to be treated with the stent but was
not covered, or protrusion due to stent jumping, and/or
elongation. Geographic miss rate is classified as 5–
15 mm (mild), 15–25 mm (moderate), >25 mm (severe),
or additional stent deployment over the stent
deployment area that was not covered, or protrusion
from the intended stent deployment area; (2) incidence
of stent fracture; (3) limb salvage rate free of above-the-
ankle amputation; (4) sustained clinical improvement
rate at 12-month follow-up; (5) repeated target lesion re-
vascularization (TLR) rate; (6) repeated target extremity
revascularization (TER) rate; (7) total reocclusion rate;
(8) comparison of angiographic variables including late
loss and binary restenosis rate; (9) ABI at 12 months;
(10) the rate of major adverse cardiovascular event
(MACE), defined as composite of all-cause death, myo-
cardial infarction, repeat percutaneous coronary inter-
vention (PCI), and stroke at 12 months.
The detailed definitions are summarized in the
Appendix.
Sample size calculation
Although patency definitions varied across trials, 1-year
patency rates in aortoiliac lesions were approximately
90 % on average from previous studies including CRISP-
US and MELODIE [22, 23]. In the case of the SCUBA™
stent, the 9-month patency rate for the SCUBA™ stent
was 99.2 % in the ACTIVE study - a prospective, multi-
center, single-arm study that defines the midterm
efficacy of a next-generation cobalt-chromium iliac stent
for the treatment of de novo and restenotic lesions in
iliac arteries [25]. However, a different definition - a ratio
of <2.4 between the duplex peak systolic velocity in the
treated vessel segment and the reference systolic
velocity - was used, unlike the more common defin-
ition. There are limited data on the 1-year primary
patency rate of the SCUBA™ stent. Based on the
MELODIE trial [23], and the European multicenter
iliac stent trial [26], the 1-year primary patency of the
SCUBA™ stent was estimated to be 88 %, and the
COMPLETE-SE™ stent was estimated to be 94.7 % in
the CRISP-US trial. Therefore, the self-expandable
COMPLETE-SE™ stent group will be the control
group, and the balloon-expandable SCUBA™ stent
group will be the experimental group.
Patency rate will be defined as absence of occlusion
and absence of >50 % stenosis in the treated segment by
quantitative coronary angiography (QCA) or if invasive
angiography is not performed, PSVR ≤2.5 when evaluated
with duplex ultrasound. On the basis of previous studies
[22, 23], we hypothesize that the expected patency rate
after stent deployment at 1 year would be 90 % for the
self-expandable stent group, and 88 % for the balloon-
expandable stent group, respectively. The predetermined
noninferiority margin δ is a 10 % difference between
treatment groups. There was clinical consensus that this
noninferiority margin would be acceptable if safety is
maintained and patients are treated more easily, regardless
of stent classification. The power analysis is based on a
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noninferiority principle. The statistical significance level is
2.5 % at one side, the power of the test is set as 80 %, and
the randomization ratio is set as 1:1. The test for propor-
tion and the chi-square method will be used. Using
standard sample size formula, it was calculated that 120
patients per group are needed for a total of 288 patients,
after accounting for a 20 % dropout rate.
Statistical analysis
The IBM SPSS 20.0 (IBM Corp., Armonk, NY, USA)
statistics program will be used for all analysis. Categor-
ical variables will be expressed as delivery rate when
comparing baseline features between the SCUBA™ and
COMPLETE-SE™ stent groups and for categorical
variables, comparisons between groups will use the chi-
square or Fisher’s exact test. Continuous variables will
be expressed as mean ± standard deviation, and for
continuous variables, comparisons between groups will
use the Student’s t test. The primary and secondary end
points will be analyzed using both intention-to-treat
analysis (all subjects assigned to a treatment group) and
per protocol analysis (only subjects who completed the
treatment protocol). Noninferiority will be considered
proven if conclusions drawn from the intention-to-treat
and per protocol analyses are consistent. Balloon-
expandable stent patency will be judged as noninferior
to that of the self-expandable stent when the lower limit
of the 95 % CI of the difference between the proportions
of patent patients at 1 year in both groups is higher than
-δ = −10 % At the end of the 12 months, cumulative
restenosis rates will be calculated. For a secondary end
point, we will summarize with descriptive statistics and
compare between treatment groups using the Student’s t
test, chi-square test, or Fisher’s exact test. Also, clinical
outcomes such as revascularization of the target vessel,
death, major cardiovascular events including myocardial
infarction and cerebral infarction, and limb salvage rates
will be analyzed using Kaplan-Meier survival estimates
and a comparison of the groups will be performed using
the log-rank test. A P value <0.05 will be considered to
be statistically significant. In order to evaluate the risk
factors for recurrence, defined as restenosis or total
occlusion, univariate and multivariate logistic regression
analysis will be performed. The present research has
concluded that there will be a very low chance of missing
data to cause bias, and therefore, missing data for the
major end points will be excluded from the analysis data.
Trial organization
Executive committee
The Executive Committee will be composed of the study
chairperson and selected members among the investiga-
tors. This committee is responsible for overseeing the
administrative progress of the study and will approve the
final trial design and protocol issued to the Data and
Safety Monitoring Board (DSMB) and the clinical sites.
This committee will also be responsible for reviewing the
final results, determining the methods of presentation and
publication, and selection of secondary projects and publi-
cations by members of the Steering Committee. The
Executive Committee also holds the right to modify or
stop the study prematurely based on recommendations
from the DSMB.
Data Safety Monitoring Board (DSMB)
The frequency of the DSMB meetings will be determined
prior to study commencement. Additionally, the DSMB
may call a meeting at any time if there is reason to suspect
that safety is an issue. The DSMB is responsible for mak-
ing recommendations regarding any safety or compliance
issues throughout the course of the study and may recom-
mend to the Executive Committee to modify or stop the
study. However, all final decisions regarding study modifi-
cations rest with the Executive Committee. All cumulative
safety data will be reported to the DSMB and reviewed on
an ongoing basis throughout enrollment and follow-up
periods to ensure patient safety. Every effort will be made
to allow the DSMB to conduct an unbiased review of
patient safety information. All DSMB reports will be made
available to the appropriate agencies upon request, but
will otherwise remain strictly confidential. Prior to the
DSMB’s first review of the data, the DSMB charter will be
drafted. The DSMB will develop a consensus understand-
ing of all trial end points and definitions used in the event
of an adjudication process. All DSMB reports will remain
strictly confidential, but will be made available to the
regulatory body upon request.
Clinical Event Adjudication Committee (CEAC)
The Clinical Event Adjudication Committee (CEAC) is
comprised of interventional and noninterventional cardi-
ologists who are not involved in the study. The CEAC is
charged with the development of specific criteria used
for the categorization of clinical events and clinical end
points in the study, which are based on protocol. At the
onset of the trial, the CEAC will establish explicit rules
outlining the minimum amount of data required and the
algorithm to be followed in order to classify a clinical
event. All members of the CEAC will be blinded to the
primary results of the trial. The CEAC will meet regu-
larly to review and adjudicate all clinical events. The
CEAC will also review and rule on all deaths that occur
throughout the trial.
Data coordination and site management
Data coordination and site management services will be
performed at the Cardiovascular Center of the Korea
University Guro Hospital.
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Timeline
A SENS-ILIAC trial timeline description is presented in
Additional file 3.
Discussion
A primary endovascular approach may be attempted in
all patients with peripheral artery obstructive disease
including iliac lesions. In performing endovascular repair
for iliac artery lesion, different strategies and types of
stents are needed, as described above. There is no
general consensus on which stents, balloon-expandable
or self-expandable stents are the most appropriate for
specific lesion of the iliac artery.
The factors associated with patency after stent im-
plantation in iliac lesion have been known to be various:
patient characteristics, lesion characteristics, and so on.
Recently, various self-expandable nitinol stents have
been manufactured with improved radial force, reduced
stent deformity or fracture, and convenient deployment
systems. Currently, self-expandable nitinol stents have
been the most widely used.
The next-generation balloon-expandable stent has
been developed. The first Assurant® balloon-expandable
stent system (Medtronic, Inc., Santa Rosa, CA, USA)
made from a cobalt-chromium alloy is to be approved
by the Food and Drug Administration (FDA) for the
treatment of narrowed iliac arteries. The mechanical
properties of the cobalt-chromium alloy allow the device
to have thinner struts and a low profile, which provide
increased flexibility while maintaining radial strength
and fluoroscopic visibility [27]. In the ACTIVE study
[25], the balloon-expandable Assurant® cobalt-chromium
iliac stent demonstrated primary patency at 9 months of
99.2 %, device and lesion success were each 97.5 %
(155/159), and the procedural success was 96.7 %.
In real-world clinical practice, physicians tend to
deploy self-expanding stents in the mid-iliac area due to
severe angulation and tortuosity for fear of iliac artery
injury including extravasation, dissection, or rupture
following high-pressure balloon inflation with longer
balloon-expandable stents. It will be of interest to see
the safety rate of balloon-expandable stents in the
tortuous mid-iliac artery.
However, because of the possibility of ‘geographic
miss’- by stent elongation or jumping during stent
deployment - which may cause stent fracture, in-stent
restenosis, and contralateral artery flow limitation, the
balloon-expandable stent has been recommended for
accurate stent deployment, especially in bifurcation
lesion, including common iliac artery ostium. It will also
be important to compare the geographic miss rate
between the balloon-expandable SCUBA stents and self-
expandable COMPLETE-SE™ stents in iliac artery lesion,
especially aortoiliac bifurcation lesion.
One of the significant limitations to previous studies is
that they were nonrandomized studies of relatively small
sample size, indirect comparisons, or expert opinions.
To date, a multicenter, randomized controlled trial for
direct comparison of efficacy and safety between self-
expandable stents and balloon-expandable stents has not
been done.
This trial was designed to evaluate the efficacy and
safety between self-expandable COMPLETE-SE™ versus
balloon-expandable SCUBA™ stents in patients undergo-
ing stent implantation in iliac artery lesions and will
provide a rationale for which choice of stent will be
optimal in iliac steno-occlusive disease, particularly with
regard to accurate lesion location.
In conclusion, we still do not know whether there is a
difference in primary patency, incidence of geographic
miss, and stent fracture between self-expandable nitinol
stents and balloon-expandable cobalt-chromium stents
(COMPLETE-SE™ versus SCUBA™) in stenotic or occlu-
sive iliac arterial lesion. We hope to address these issues
in the SENS-ILIAC trial where we have enrolled a large
unselected population of patients treated with stent
implantation for significant iliac arterial disease.
Trial status
This study is ongoing and is recruiting.
Appendix
1. End points definitions
– Primary patency: defined as stenosis of at least 50 %
of the luminal diameter according to the worst
angiographic view at the narrowest site within the
treated segment plus the 10-mm segments proximal
and distal to the treated segment by catheter angi-
ography or CT angiography; PSVR ≥2.5 (PSVR =
peak systolic velocity within the area of stenosis
divided by peak systolic velocity in a normal adja-
cent proximal artery segment) or total occlusion by
duplex ultrasound
– Geographic miss according miss grade (mild, moderate,
severe): geographic miss is classified as 5–15 mm
(mild), 15–25 mm (moderate), >25 mm (severe), or
additional stent deployment over the stent deployment
area that was not covered, or protrusion from the
intended stent deployment area
– Stent fracture rate according fracture grade (minor,
moderate, severe), [28] plain X-ray examinations for
the stent fracture are used or performed using at
least two different angulations (30 to 45° difference)
and the highest available magnification. Stent frac-
ture is classified as minor (single strut fracture),
moderate (fracture of more than two struts), or
severe (complete separation of stent segments)
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– Target lesion revascularization (TLR): defined as any
repeat percutaneous intervention of the target lesion
or bypass surgery of the target vessel performed for
restenosis because of a return of ischemic symptoms,
decrease of at least one Rutherford category,
decrease in the ankle brachial index of >0.15, or
restenosis of >50 % as measured by catheter
angiography. The target lesion is defined as the
treated segment from 10 mm proximal to the stent
and to 10 mm distal to the stent
– Target extremity revascularization (TER): defined as
any repeat percutaneous intervention of the target
extremity or bypass surgery of the target extremity
performed for restenosis because of a return of
ischemic symptoms, decrease of at least one
Rutherford category, decrease in the ankle brachial
index of >0.15, or restenosis of >50 % as measured
by catheter angiography
– Limb salvage: defined as survival free of amputation.
Amputation is defined as above-ankle amputation of
the index limb
– Sustained clinical improvement rate [29, 30] defined
as persistent ABI value ≥0.15 and persistent
improvement of ≥1 class according to Rutherford
throughout follow-up when compared with baseline
without the need for repeat TLR in surviving pa-
tients. Late loss: defined as a change in MLD from
final angiogram to follow-up
– Major adverse cardiac events (MACE): defined as
composite of all-cause death, myocardial infarc-
tion, cerebrovascular stroke, and target lesion
revascularization
2. Immediate outcomes
– Acute lesion success: defined as a residual stenosis
of ≤30 % without flow-limiting dissection in the
worst angiographic view
– Definition of suboptimal result: residual pressure
gradient of >15 mmHg, residual stenosis of >30 %,
or flow-limiting dissection
– Acute hemodynamic success: defined as a ≥0.15
improvement in the ankle-brachial index from pre-
procedure to immediately postprocedure (discharge)
– Clinical success: defined as an improvement of
baseline symptoms by at least one Rutherford
category that was sustained throughout follow-up
with no additional intervention
3. QCA data definition and variables
– Reference vessel diameter (obtained from averaging
5-mm segments proximal and distal to the lesion)
– Minimal luminal diameter (MLD)
– Acute gain (change in MLD from baseline to
postintervention)
– Late loss (change in MLD from the final angiogram
to follow-up)
– Percent diameter stenosis
– Total reocclusion rate
– Patency (<50 %) rate
4. Ankle-brachial index (ABI) is calculated as following:
– Measurement of highest systolic pressure in both
arms
– Measurement of systolic pressure in both legs
– Use highest ankle pressure (dorsalis pedis or
posterior tibialis) for each leg
– Calculate ratio of each ankle to brachial pressure by
dividing each ankle by highest brachial pressure.
Bleeding/hemorrhagic complications
5. An episode of bleeding is defined by the Thrombolysis
in Myocardial Infarction (TIMI) criteria as:
– Major: overt clinical bleeding (or documented
intracranial or retroperitoneal hemorrhage) associated
with a drop in hemoglobin (Hgb) of greater than 5 g/
dl (0.5 g/l) or in hematocrit (Hct) of greater than 15 %
(absolute) *Note: a patient who experiences an
intracranial hemorrhage should be considered to have
a major hemorrhage
– Minor: overt clinical bleeding associated with a fall
in hemoglobin of 3 to less than or equal to 5 g/dl
(0.5 g/l) or in hematocrit of 9 % to less than or
equal to 15 % (absolute)
– None: no bleeding event that meets the major or
minor definition
*Note: in calculating the fall in hemoglobin or
hematocrit, a transfusion of whole blood or packed red
blood cells is counted as 1 g/dl (0.1 g/l) hemoglobin or
3 % absolute in hematocrit. This would be in addition to
the actual fall in hemoglobin or hematocrit.
*To account for transfusion, hemoglobin and hematocrit
measurements will be adjusted for any packed red blood
cells or whole blood given between baseline and post-
transfusion measurements. A transfusion of one unit of
blood will be assumed to result in an increase of 1 g/dl in
Hgb or of 3 % in Hct. Thus, to calculate the true change
in Hgb or Hct if there has been an intervening transfusion
between two blood measurements, the following calcula-
tions should be performed: Hgb =[baseline Hgb-
posttransfusion Hgb] + [number of transfused units] Hct
= [baseline Hct-posttransfusion Hct] + [number of trans-
fused units × 3].
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The following will be classified as “instrumented”
major bleeding that is considered to be associated with
the catheterization laboratory visit:
– Major percutaneous entry site: bleeding occurred at
the percutaneous entry site during or after the
catheterization laboratory visit until discharge. The
bleeding should require a transfusion and/or
prolong the health care facility stay, and/or cause a
drop in Hgb >5 g/dl
– Bleeding at the percutaneous entry site can be external,
or a hematoma >10 cm for femoral access or >2 cm
for radial access, or >5 cm for brachial access
– Major retroperitoneal, gastrointestinal, and genital/
urinary: bleeding occurred during or after the
catheterization laboratory visit until discharge. The
bleeding either requires surgical intervention (e.g.,
to relieve nerve compression), and/or requires a
transfusion and/or prolongs the health care facility
stay, and/or causes a drop in hemoglobin >5.0 g/dl
– Major other/unknown: bleeding occurred at other or
unknown locations during or after the catheterization
laboratory visit until discharge. The bleeding should
require a transfusion and/or prolong the health care
facility stay, and/or cause a drop in Hgb > 5 g/dl
Stent size and compatibility: compatible wire system:
0.035” or 0.018” wire system. Diameter and length of
self-expandable COMPLETE-SE™ stent are 5–10 mm
and 20, 40, 60, 80, 100, 120, and 150 mm, respectively.
Diameter and length of balloon-expandable SCUBA™
stent are 6–10 mm and 20, 30, 40, and 60 mm,
respectively.
Additional files
Additional file 1: SPIRIT checklist. (DOCX 60 kb)
Additional file 2: Consent form. (DOCX 28 kb)
Additional file 3: The schedule of enrollment, interventions, and
assessments. (DOCX 22 kb)
Abbreviations
ABI, ankle-brachial index; CEAC, Clinical Event Adjudication Committee; CIRI,
Cardiovascular Intervention Research Institute; CLI, critical limb ischemia; CT,
computed tomography; CTO, chronic total occlusion; DSMB, Data and Safety
Monitoring Board; FDA, Food and Drug Administration; Hct, hematocrit; Hgb,
hemoglobin; MACE, major adverse cardiovascular event; MLD, minimal luminal
diameter; PCI, percutaneous coronary intervention; PSVR, peak systolic velocity
ratio; PTA, percutaneous transluminal angioplasty; QCA, quantitative coronary
angiography; RVD, reference vessel diameter; SFA, superficial femoral artery;
TASC, TransAtlantic Inter-Society Consensus; TER, target extremity revascularization;
TLR, target lesion revascularization
Acknowledgements
This study was supported by a grant from the Medtronic Company, Korea.
Authors’ contributions
WGC contributed to the initial conception and design of the whole study,
acquisition of the data, critical establishment/management of the whole
database, and wrote the manuscript. SWR contributed to the initial
conception and design of the whole study, critical acquisition of the data,
and gave approval of the final version of the manuscript. CUC was involved
in the drafting of the manuscript and critical revision of the study design.
EJK was involved in the drafting of the manuscript and critical revision of the
study design. DJO was involved in the drafting of the manuscript and critical
revision of the study design. YHC was involved in the drafting of the
manuscript and critical revision of the study design. SHP was involved in the
drafting of the manuscript and critical revision of the study design. SJL
contributed to the critical acquisition of the data and initial conception of
the study design. AYH contributed to the critical acquisition of the data and
initial conception of the study design. YGK contributed to the critical
acquisition of the data and initial conception of the study design. SMP
contributed to the critical acquisition of the data and initial conception of
the study design. KCK contributed to the critical acquisition of the data and
initial conception of the study design. JHK contributed to the critical
acquisition of the data and initial conception of the study design. MWK
contributed to the critical acquisition of the data and initial conception of
the study design. SMK contributed to the critical acquisition of the data and
initial conception of the study design. JHB contributed to the critical
acquisition of the data and initial conception of the study design. JMB
contributed to the critical acquisition of the data and initial conception of
the study design. WYK contributed to the critical acquisition of the data and
initial conception of the study design. JBS contributed to the critical
acquisition of the data and initial conception of the study design. WYJ
contributed to the critical acquisition of the data and critical reading/revision
of the study manuscript. JHC contributed to the critical acquisition of the
data and initial conception of the study design. DHK contributed to the
critical acquisition of the data and initial conception of the study design. JHA
contributed to the critical acquisition of the data and initial conception of
the study design. SHK contributed to the critical acquisition of the data and
initial conception of the study design. JYJ contributed to the critical
acquisition of the data and initial conception of the study design. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Upon trial completion, the main manuscript with trial results, whether positive,
negative or neutral, will be submitted to a major clinical journal for peer review
and publication.
Ethics approval and consent to participate
This study has been approved by the institutional review boards of the
investigators’ centers: Konkuk University Chungju Hospital, reference number
2013–008; Korea University Guro Hospital, reference number MD12014;
Mung-Gi General Hospital, reference number 12–110; Soonchunhyang
University Cheonan Hospital, reference number 2012–05; Kangwon University
Hospital, reference number KWNUH-2013-04-007-001; Severance Hospital,
reference number 1-2012-0061; Chuncheon Sacred Heart Hospital, reference
number 2014–65; Incheon Sa-Rang General Hospital, reference number
2013–1; Chunnam University Hospital, reference number CNUH-2013-009;
Hanyang Universicty Medical Center Hanmaeum Hospital, reference number
MD2013-0004; Chungbuk University Hospital, reference number CBNUH-
2013-01-013-002; Konyang University Hospital, reference number 13–04;
Incheon Hanlim General Hospital, reference number 2; Kwangju Veterans
General Hospital, reference number 2013-5-2; Seoul University Boraemea
Hospital, reference number 20130806/26-2013-69/08216; St. Carollo Hospital,
reference number SCH 2013–117; Soonchunhyang University Gumi Hospital,
reference number 2014–05. The investigator will obtain their written approval
before being allowed to conduct and participate in the study. The investigator
is also responsible for fulfilling any conditions of approval imposed by the
institutional review board, such as regular reporting, study timing, and so on.
The investigator will provide the Sponsor with copies of such approvals
and reports.
Choi et al. Trials  (2016) 17:302 Page 9 of 10
Author details
1Department of Internal Medicine, School of Medicine, Konkuk University,
Chungju, Korea. 2Cardiovascular Center, Korea University Guro Hospital, 80,
Guro-dong, Guro-gu, Seoul 152-703, Korea. 3Cardiovascular Center, Myong-Ji
General Hospital, Ilsan, Korea. 4Department of Cardiology, Soonchunhyang
University Cheonan Hospital, Cheonan, Korea. 5Cardiovascular Center,
Kangwon University, Chuncheon, Korea. 6Cardiovascular Center, Severance
Hospital, Seoul, Korea. 7Department of Cardiology, Chuncheon Sacred Heart
Hospital, Chuncheon, Korea. 8Cardiovascular Center, Incheon Sa-Rang
General Hospital, Incheon, Korea. 9Cardiovascular Center, Chunnam University
Hospital, Kwangu, Korea. 10Department of Cardiology, Hanyang University
Medical Center Hanmaeum Hospital, Changwon, Korea. 11Cardiovascular
Center, Chungbuk University, Cheongju, Korea. 12Cardiovascular Center,
Konyang University Hospital, Daejon, Korea. 13Cardiovascular Center, Incheon,
Hanlim General Hospital, Incheon, Korea. 14Cardiovascular Center, Kwanju
Veterans General Hospital, Kwangju, Korea. 15Cardiovascular Center, Seoul
University Boraemea Hospital, Seoul, Korea. 16Department of Cardiology, St.
Carollo Hospital, Suncheon, Korea. 17Cardiovascular Center, Soonchunhyang
University Gumi Hospital, Gumi, Korea.
Received: 24 June 2015 Accepted: 8 June 2016
References
1. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal
angioplasty for the treatment of critical limb ischemia: a 10-year experience.
J Vasc Surg. 2005;41:423–35.
2. Timaran CH, Prault TL, Stevens SL, Freeman MB, Goldman MH. Iliac artery
stenting versus surgical reconstruction or TASC (TransAtlantic Inter-Society
Consensus) type B and type C iliac lesions. J Vasc Surg. 2003;38:272–8.
3. Schurmann K, Mahnken A, Meyer J, Haage P, Chalabi K, Peters I, Günther
RW, Vorwerk D. Long-term results 10 years after iliac arterial stent
placement. Radiology. 2002;224:731–8.
4. Murphy TP, Ariaratnam NS, Carney WI, Marcaccio EJ, Slaiby JM, Soares GM,
Kim HM. Aortoiliac insufficiency: long-term experience with stent placement
for treatment. Radiology. 2004;231:243–9.
5. Klein WM, van der Graaf Y, Seegers J, Spithoven JH, Buskens E, van Baal JG,
Buth J, Moll FL, Overtoom T T, van Sambeek MR, Mali WP. Dutch iliac stent
trial: long-term results in patients randomized for primary or selective stent
placement. Radiology. 2006;238:734–44.
6. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG,
TASC II Working Group. Inter-society consensus for the management of
peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67.
7. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous
transluminal angioplasty and stent placement for aortoiliac occlusive
disease. Radiology. 1997;204:87–96.
8. Hood DB, Hodgson KJ. Percutaneous transluminal angioplasty and stenting
for iliac artery occlusive disease. Surg Clin North Am. 1999;79:575–96.
9. Powell RJ, Fillinger M, Walsh DB, Zwolak R, Cronenwett JL. Predicting
outcome of angioplasty and selective stenting of multisegment iliac artery
occlusive disease. J Vasc Surg. 2000;32:564–9.
10. Powell RJ, Fillinger M, Bettmann M, Jeffery R, Langdon D, Walsh DB, Zwolak R,
Hines M, Cronenwett JL. The durability of endovascular treatment of
multisegment iliac occlusive disease. J Vasc Surg. 2000;31:1178–84.
11. Saket RR, Razavi MK, Padidar A, Kee ST, Sze DY, Dake MD. Novel
intravascular ultrasound-guided method to create transintimal arterial
communications: initial experience in peripheral occlusive disease and
aortic dissection. J Endovasc Ther. 2004;11:274–80.
12. Kashyap VS, Pavkov ML, Bena JF, Sarac TP, O’Hara PJ, Lyden SP, Clair DG.
The management of severe aortoiliac occlusive disease: endovascular
therapy rivals open reconstruction. J Vasc Surg. 2008;48:1451–7.
13. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP,
Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E,
Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van
Sambeek M, Zeller T. ESC Guidelines on the diagnosis and treatment of
peripheral artery diseases: document covering atherosclerotic disease of
extracranial carotid and vertebral, mesenteric, renal, upper and lower
extremity arteries: the Task Force on the Diagnosis and Treatment of
Peripheral Artery Diseases of the European Society of Cardiology. Eur Heart
J. 2011;32:2851–906.
14. Ichihashi S, Higashiura W, Itoh H, Sakaguchi S, Nishimine K, Kichikawa K.
Long-term outcomes for systematic primary stent placement in complex
iliac artery occlusive disease classified according to Trans-Atlantic Inter-
Society Consensus (TASC)-II. J Vasc Surg. 2011;53:992–9.
15. Schillinger M, Minar E. Endovascular stent implantation for treatment of
peripheral artery disease. Eur J Clin Invest. 2007;37:165–70.
16. Hassen-Khodja R, Sala F, Declemy S, Bouillanne PJ, Batt M, Staccini P. Value
of stent placement during percutaneous transluminal angioplasty of the
iliac arteries. J Cardiovasc Surg. 2001;42:369–74.
17. Murphy TP, Webb MS, Lambiase RE, Haas RA, Dorfman GS, Carney Jr WI,
Morin CJ. Percutaneous revascularization of complex iliac artery stenoses
and occlusions with use of Wallstents: three-year experience. J Vasc Interv
Radiol. 1996;7:21–7.
18. Stoeckel D, Pelton A, Duerig T. Self-expanding nitinol stents: material and
design considerations. Eur Radiol. 2004;14:292–301.
19. Dyet JF, Watts WG, Ettles DF, Nicholson AA. Mechanical properties of
metallic stents: how do these properties influence the choice of stent for
specific lesions? Cardiovasc Intervent Radiol. 2000;23:47–54.
20. Duda SH, Wiskirchen J, Tepe G, Bitzer M, Kaulich TW, Stoeckel D, Claussen
CD. Physical properties of endovascular stents: an experimental comparison.
J Vasc Interv Radiol. 2000;11:645–54.
21. Henry M, Klonaris C, Amor M, Henry I, Tzvetanov K. State of the art: which
stent for which lesion in peripheral interventions? Tex Heart Inst J.
2000;27:119–26.
22. Ponec D, Jaff MR, Swischuk J, Feiring A, Laird J, Mehra M, Popma JJ, Donohoe D,
Firth B, Keim E, Snead D; CRISP Study Investigators. The Nitinol SMART stent vs
Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc
Interv Radiol. 2004;15:911–8.
23. Stockx L, Poncyljusz W, Krzanowski M, Schroë H, Allocco DJ, Dawkins KD,
MELODIE Investigators. Express LD vascular stent in the treatment of iliac
artery lesions: 24-month results from the MELODIE trial. J Endovasc Ther.
2010;17:633–41.
24. Grenacher L, Rohde S, Gänger E, Deutsch J, Kauffmann GW, Richter GM. In
vitro comparison of self-expanding versus balloon-expandable stents in a
human ex vivo model. Cardiovasc Intervent Radiol. 2006;29:249–54.
25. Molnar RG, Gray WA, ACTIVE Trial Investigators. Sustained patency and
clinical improvement following treatment of atherosclerotic iliac artery
disease using the Assurant cobalt iliac balloon-expandable stent system.
J Endovasc Ther. 2013;20:94–103.
26. Reekers JA, Vorwerk D, Rousseau H, Sapoval MR, Gaines PA, Stockx L,
Delcour CP, Raat H, Voshage G, Biamino G, Hoogeveen YL. Results of a
European multicentre iliac stent trial with a flexible balloon expandable
stent. Eur J Vasc Endovasc Surg. 2002;24:511–5.
27. Marrey RV, Burgermeister R, Grishaber RB, Ritchie RO. Fatigue and life
prediction for cobalt-chromium stents: a fracture mechanics analysis.
Biomaterials. 2006;27:1988–2000.
28. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M, Biamino G,
Schmidt A. Prevalence and clinical impact of stent fractures after
femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–5.
29. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN.
Recommended standards for reports dealing with lower extremity ischemia:
revised version. J Vasc Surg. 1997;26:517–38.
30. Diehm N, Baumgartner I, Jaff M, Do DD, Minar E, Schmidli J, Diehm C,
Biamino G, Vermassen F, Scheinert D, van Sambeek MR, Schillinger M. A call
for uniform reporting standards in studies assessing endovascular treatment
for chronic ischaemia of lower limb arteries. Eur Heart J. 2007;28:798–805.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Choi et al. Trials  (2016) 17:302 Page 10 of 10
